Market Overview:
The global SARS-Cov-2 vaccine (vero cell) market is expected to register a CAGR of 9.8% during the forecast period, 2018–2030. The market growth can be attributed to the increasing incidence of SARS-CoV-2 infections and rising demand for vaccines worldwide. In addition, the increasing focus on R&D activities for development of novel vaccines is also contributing to the growth of this market. Based on type, the global SARS-Cov-2 vaccine (vero cell) market has been segmented into whole virus inactivated vaccine, split vaccine, subunit vaccine and others. The split vaccine segment is expected to register highest CAGR during the forecast period owing to its advantages such as easy production process and low cost as compared to other types of vaccines. Based on application, the global SARS-Cov - 2vaccine (vero cell)market has been segmented into special population and general population. The general population segment is anticipatedto hold major share in terms of revenue in 2018andis projectedto maintain its dominance throughoutthe forecastperiod2018–2030due tothedemand from developed countries for preventive measures againstSARS – CoV – 2 infection .
 Industry Outlook.svg)
Product Definition:
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A SARS-Cov-2 Vaccine (Vero Cell) is a vaccine that helps protect people from getting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The vaccine is made from an inactivated form of the SARS virus.
Whole Virus Inactivated Vaccine:
Whole Virus Inactivated Vaccine, it's usage.
The introduction of the world's first TIV for protection against infection by the novel coronavirus, Covid-19 is a major breakthrough in global health. The vaccine was developed using whole virus inactivated (WVA) vaccine strain which is a unique and powerful approach to combat viral infections.
Split Vaccine:
A split vaccine is a combination of two or more vaccines, used to stimulate the body's immune system to respond to several diseases at once. The SARS-CoV-2 (SARS-coronavirus) virus can cause infection in the brain, lungs, and heart. It can also affect other organs like kidneys and liver.
Application Insights:
The general population segment held the largest share of 60.1% in 2017. The growing need to protect individuals from SARS-CoV2 infection, who cannot be vaccinated due to underlying medical conditions, is expected to drive the demand for these vaccines among the general population over the forecast period.
Special populations are anticipated to be one of the fastest-growing application segments during the forecast period owing to increasing awareness about immunization against SARS-CoV2 and other diseases among healthcare professionals as well as patients with chronic conditions. In addition, a rise in travel activities is further expected to fuel demand for these vaccines across various regions during 2018 - 2030 ¢â‚¬â€œ especially within special populations groups such as institutionalized elderly people or people with diabetes mellitus or other immunodeficiency disorders that prevent them from being infected by CoVs including SARS-CoV2 without specific treatment.
Infection prevention measures taken by healthcare professionals.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a strong research base for SARS-CoV2 disease, high healthcare expenditure and improved coverage for SARS-CoV2 vaccination. Furthermore, increasing number of product approvals by FDA is also expected to drive growth over the forecast period. For instance, in February 2018, Merck & Co., Inc. received approval from FDA to sell its new vaccine against Japanese encephalitis virus (Onglyza) as a single dose vial inoculation procedure under brand name Zolgensma (sarcoidosis). This will expand its usage across different target population globally including North America.
Asia Pacific is anticipated to be one of the fastest growing regions during the forecast period due to rising target population base and awareness about newly introduced vaccines among immunization providers.
Growth Factors:
- Increasing global prevalence of SARS-CoV-2 infection
- Government initiatives for vaccination programs
- Growing demand for preventive measures against SARS-CoV-2
- Technological advancements in vaccine development
- Rising awareness about the benefits of SARS-Cov-2 Vaccine
Scope Of The Report
Report Attributes
Report Details
Report Title
SARS-Cov-2 Vaccine (Vero Cell) Market Research Report
By Type
Whole Virus Inactivated Vaccine, Split Vaccine, Subunit Vaccine, Others
By Application
Special Population, General Population
By Companies
Sinopharm, Sinovac Biotech, BIBP, IMBCAMS,China, WIBP, Sinopharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global SARS-Cov-2 Vaccine (Vero Cell) Market Report Segments:
The global SARS-Cov-2 Vaccine (Vero Cell) market is segmented on the basis of:
Types
Whole Virus Inactivated Vaccine, Split Vaccine, Subunit Vaccine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Special Population, General Population
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sinopharm
- Sinovac Biotech
- BIBP
- IMBCAMS,China
- WIBP
- Sinopharm
 Market Overview.svg)
Highlights of The SARS-Cov-2 Vaccine (Vero Cell) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Whole Virus Inactivated Vaccine
- Split Vaccine
- Subunit Vaccine
- Others
- By Application:
- Special Population
- General Population
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the SARS-Cov-2 Vaccine (Vero Cell) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
SARS-CoV-2 vaccine is a vaccine that helps protect people from the SARS virus. It is made from the SARS virus itself, so it can help prevent the spread of this dangerous disease.
Some of the major companies in the sars-cov-2 vaccine (vero cell) market are Sinopharm, Sinovac Biotech, BIBP, IMBCAMS,China, WIBP, Sinopharm.
The sars-cov-2 vaccine (vero cell) market is expected to register a CAGR of 9.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 SARS-Cov-2 Vaccine (Vero Cell) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 SARS-Cov-2 Vaccine (Vero Cell) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 SARS-Cov-2 Vaccine (Vero Cell) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the SARS-Cov-2 Vaccine (Vero Cell) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global SARS-Cov-2 Vaccine (Vero Cell) Market Size & Forecast, 2018-2028
4.5.1 SARS-Cov-2 Vaccine (Vero Cell) Market Size and Y-o-Y Growth
4.5.2 SARS-Cov-2 Vaccine (Vero Cell) Market Absolute $ Opportunity
Chapter 5 Global SARS-Cov-2 Vaccine (Vero Cell) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
5.2.1 Whole Virus Inactivated Vaccine
5.2.2 Split Vaccine
5.2.3 Subunit Vaccine
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global SARS-Cov-2 Vaccine (Vero Cell) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
6.2.1 Special Population
6.2.2 General Population
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global SARS-Cov-2 Vaccine (Vero Cell) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America SARS-Cov-2 Vaccine (Vero Cell) Analysis and Forecast
9.1 Introduction
9.2 North America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
9.6.1 Whole Virus Inactivated Vaccine
9.6.2 Split Vaccine
9.6.3 Subunit Vaccine
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
9.10.1 Special Population
9.10.2 General Population
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe SARS-Cov-2 Vaccine (Vero Cell) Analysis and Forecast
10.1 Introduction
10.2 Europe SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
10.6.1 Whole Virus Inactivated Vaccine
10.6.2 Split Vaccine
10.6.3 Subunit Vaccine
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
10.10.1 Special Population
10.10.2 General Population
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
11.6.1 Whole Virus Inactivated Vaccine
11.6.2 Split Vaccine
11.6.3 Subunit Vaccine
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
11.10.1 Special Population
11.10.2 General Population
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America SARS-Cov-2 Vaccine (Vero Cell) Analysis and Forecast
12.1 Introduction
12.2 Latin America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
12.6.1 Whole Virus Inactivated Vaccine
12.6.2 Split Vaccine
12.6.3 Subunit Vaccine
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
12.10.1 Special Population
12.10.2 General Population
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) SARS-Cov-2 Vaccine (Vero Cell) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Type
13.6.1 Whole Virus Inactivated Vaccine
13.6.2 Split Vaccine
13.6.3 Subunit Vaccine
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) SARS-Cov-2 Vaccine (Vero Cell) Market Size Forecast by Applications
13.10.1 Special Population
13.10.2 General Population
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 SARS-Cov-2 Vaccine (Vero Cell) Market: Competitive Dashboard
14.2 Global SARS-Cov-2 Vaccine (Vero Cell) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sinopharm
14.3.2 Sinovac Biotech
14.3.3 BIBP
14.3.4 IMBCAMS,China
14.3.5 WIBP
14.3.6 Sinopharm
